Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1995 Jan;221(1):89–99. doi: 10.1097/00000658-199501000-00011

Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.

Y Nio 1, K Tamura 1, M Tsubono 1, K Kawabata 1, Y Masai 1, H Hayashi 1, S Ishigami 1, S Araya 1, M Imamura 1
PMCID: PMC1234499  PMID: 7826166

Abstract

OBJECTIVE: The authors compare and characterize the changes in chemosensitivity between the original tumors before chemotherapy and recurrent tumors after responses. SUMMARY BACKGROUND DATA: The drug resistance in clinical chemotherapy appears to be different from that in experimental chemotherapy, and the profile and mechanisms of clinical drug resistance in recurrent tumors, especially after successful chemotherapy has scarcely been studied. METHODS: Applied chemotherapies were selected out of four agents, cisplatin (CDDP), adriamycin (ADR), mitomycin-C (MMC) and 5-fluorouracil (5-FU), singly or in combinations by a DNA synthesis inhibition assay, by which the sensitivity of recurrent tumors was assessed. Responses were defined according to the standard criteria, and successful chemotherapy indicates complete response (CR) or partial response (PR) for solid tumors and complete disappearance for malignant effusion. RESULTS: In 37 patients, the effectiveness of four agents were compared between before chemotherapy and after recurrence, and the response lasted between 2 and 26 months (mean +/- SD, 7.7 +/- 5.5). The results suggest that locally recurred tumors may become resistant to the agents previously administered; by contrast, distantly recurred tumors may not necessarily become resistant to the agents administered. The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR. Twenty-three of 37 recurrent tumors were re-treated with chemotherapies selected according to the sensitivity assay, singly or in combination with a biologic response modifier (BRM)--a streptococcal preparation, OK-432, or interferon-alpha. Responses were seen in 1 of 13 solid recurrent tumors and in 6 of 10 recurrent effusions. Responses were seen only when the patients were treated with a combination of chemotherapy and BRM. CONCLUSION: There may be a notable differences in the basic biologic characteristics of tumor cells with respect to local versus distant recurrences, and between effusion versus solid recurrences. Various approaches, including a combination of chemotherapy and BRM, therefore, may have to be applied to overcome these drug resistances in practical chemotherapies for recurrent tumors.

Full text

PDF
89

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  2. Barrows L. R., Borchers A. H., Paxton M. B. Transfectant CHO cells expressing O6-alkylguanine-DNA-alkyltransferase display increased resistance to DNA damage other than O6-guanine alkylation. Carcinogenesis. 1987 Dec;8(12):1853–1859. doi: 10.1093/carcin/8.12.1853. [DOI] [PubMed] [Google Scholar]
  3. Batist G., Tulpule A., Sinha B. K., Katki A. G., Myers C. E., Cowan K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986 Nov 25;261(33):15544–15549. [PubMed] [Google Scholar]
  4. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  5. Berek J. S., Hacker N. F., Lichtenstein A., Jung T., Spina C., Knox R. M., Brady J., Greene T., Ettinger L. M., Lagasse L. D. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res. 1985 Sep;45(9):4447–4453. [PubMed] [Google Scholar]
  6. Bungo M., Fujiwara Y., Kasahara K., Nakagawa K., Ohe Y., Sasaki Y., Irino S., Saijo N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 1990 May 1;50(9):2549–2553. [PubMed] [Google Scholar]
  7. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  8. Deffie A. M., Batra J. K., Goldenberg G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989 Jan 1;49(1):58–62. [PubMed] [Google Scholar]
  9. Fidler I. J., Poste G. The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol. 1985 Sep;12(3):207–221. [PubMed] [Google Scholar]
  10. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  11. Goldie J. H., Coldman A. J. Analyzing the patterns of treatment failure. J Clin Oncol. 1986 Jun;4(6):825–826. doi: 10.1200/JCO.1986.4.6.825. [DOI] [PubMed] [Google Scholar]
  12. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  13. Harnett P. R., Tattersall M. H., Coates A. S., van Couten R., Forbes J. Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1601–1605. doi: 10.1016/0277-5379(87)90437-8. [DOI] [PubMed] [Google Scholar]
  14. Heppner G. H. Tumor heterogeneity. Cancer Res. 1984 Jun;44(6):2259–2265. [PubMed] [Google Scholar]
  15. Jansen G., Westerhof G. R., Kathmann I., Rademaker B. C., Rijksen G., Schornagel J. H. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance. Cancer Res. 1989 May 1;49(9):2455–2459. [PubMed] [Google Scholar]
  16. Kartner N., Riordan J. R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983 Sep 23;221(4617):1285–1288. doi: 10.1126/science.6137059. [DOI] [PubMed] [Google Scholar]
  17. Laskin J. D., Evans R. M., Slocum H. K., Burke D., Hakala M. T. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 1979 Feb;39(2 Pt 1):383–390. [PubMed] [Google Scholar]
  18. Masuda H., Ozols R. F., Lai G. M., Fojo A., Rothenberg M., Hamilton T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988 Oct 15;48(20):5713–5716. [PubMed] [Google Scholar]
  19. Mekhail-Ishak K., Hudson N., Tsao M. S., Batist G. Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res. 1989 Sep 1;49(17):4866–4869. [PubMed] [Google Scholar]
  20. Nio Y., Imai S., Shiraishi T., Tsubono M., Morimoto H., Tseng C. C., Tobe T. Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay. Cancer. 1990 Mar 15;65(6):1273–1278. doi: 10.1002/1097-0142(19900315)65:6<1273::aid-cncr2820650603>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  21. Nio Y., Zighelboim J., Berek J., Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer. 1989 Jul 15;64(2):434–441. doi: 10.1002/1097-0142(19890715)64:2<434::aid-cncr2820640216>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  22. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  23. Rambaldi A., Introna M., Colotta F., Landolfo S., Colombo N., Mangioni C., Mantovani A. Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer. 1985 Jul 15;56(2):294–301. doi: 10.1002/1097-0142(19850715)56:2<294::aid-cncr2820560216>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  24. Samuels B. L., Murray J. L., Cohen M. B., Safa A. R., Sinha B. K., Townsend A. J., Beckett M. A., Weichselbaum R. R. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res. 1991 Jan 15;51(2):521–527. [PubMed] [Google Scholar]
  25. Schlag P., Schreml W. Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay. Cancer Res. 1982 Oct;42(10):4086–4089. [PubMed] [Google Scholar]
  26. Sirachý J. An approach to the problem of heterogeneity of human tumour-cell populations. Br J Cancer. 1979 May;39(5):570–577. doi: 10.1038/bjc.1979.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Torisu M., Katano M., Kimura Y., Itoh H., Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery. 1983 Mar;93(3):357–364. [PubMed] [Google Scholar]
  28. Uchida A., Micksche M. Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells. Int J Cancer. 1983 Jan 15;31(1):1–5. doi: 10.1002/ijc.2910310102. [DOI] [PubMed] [Google Scholar]
  29. Valagussa P., Tancini G., Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer. 1986 Oct 1;58(7):1411–1417. doi: 10.1002/1097-0142(19861001)58:7<1411::aid-cncr2820580705>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  30. Watanabe Y., Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer. 1984 Jan 15;53(2):248–253. doi: 10.1002/1097-0142(19840115)53:2<248::aid-cncr2820530211>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES